▋ Huierkangxin provides high-quality immune protection for maternal and infant health

Recently, the mid-term summary meeting for the research project on the safety and immune efficacy of the quadrivalent influenza virus subunit vaccine (Hui'erkangxin®) for pregnant women was held at the First Affiliated Hospital of Chongqing Medical University.
This research was jointly initiated by the company, the First Affiliated Hospital of Chongqing Medical University, and the Yuzhong District Center for Disease Control and Prevention of Chongqing on March 1, 2025. The initiation of this research marks a significant milestone for influenza prevention and control among pregnant women in China. It provides crucial data support for increasing the influenza vaccination rate among pregnant women, reducing influenza-related health risks for both mothers and infants, and establishing a health protection barrier during pregnancy. Furthermore, it fills the gap in scientific evidence from the Chinese population, supporting the international consensus that influenza vaccination during pregnancy is safe.

▋ Pay attention to the health of pregnant women and build an immune barrier against influenza

Pregnant women constitute one of the high-risk groups for influenza and related complications. During pregnancy, numerous physiological and immune system changes increase the susceptibility of pregnant women to influenza viruses, leading to relatively severe clinical symptoms upon infection. Studies have found that pregnant women, when infected with influenza, not only face a higher risk of severe illness and death compared to non-pregnant individuals, but also experience an increased risk of adverse pregnancy outcomes, such as spontaneous abortion, premature delivery, and congenital fetal defects.
Vaccination with the quadrivalent influenza virus subunit vaccine can significantly reduce the risk of pregnant women contracting the influenza virus, greatly decreasing the likelihood of severe illness, premature birth, stillbirth, and congenital fetal defects. Additionally, it can provide protection to the developing fetus and newborns aged 0-6 months through maternal antibodies.

▋ High-quality vaccines, safeguarding the health of the entire population

The quadrivalent influenza virus subunit vaccine (Hui'erkangxin®) utilizes a unique process to extract key effective antigens (HA and NA) from influenza viruses. While ensuring high purity (≥85%) and good safety, it exhibits excellent immunogenicity. The product meets multiple quality standards that surpass those of the Chinese and European Union Pharmacopoeia, reaching an internationally advanced level. The latest "Technical Guidelines for Influenza Vaccine Prevention and Vaccination in China (2025-2026)" also includes phase III clinical data for the quadrivalent influenza virus subunit vaccine across the entire population, and proposes that compared to split vaccines, subunit vaccines have higher purity of effective antigen components due to the removal of internal viral proteins, offering better safety.
In September this year, this product was approved for use by individuals aged 6 months and above, becoming the first and only fully-dosed quadrivalent influenza virus subunit vaccine approved for the entire population in China. This high-quality vaccine, characterized by high purity, low adverse reactions, good safety, and superior immune effects, conforms to the international vaccine development trend, achieving a unified dosage form for individuals aged 6 months and above. This greatly enhances the convenience of vaccination and management, providing broader and more efficient immune protection for influenza prevention and control in China.

▋ About Ab&B Bio

Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) is committed to the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines utilizing new technological methods. Aiming at international standards, we carry out independent innovative research and development. Up to now, we have obtained multiple clinical trial approvals for new drugs and are orderly conducting clinical trials and NDA submissions.
"Rather than simply copying, aiming at international trends, and developing innovative vaccines are the founding principles of Zhonghui Biotech. Caring for life and safeguarding health are the missions of Zhonghui Biotech! Zhonghui Biotech will carry forward the spirit of innovation, pragmatism, self-discipline, integrity, and perseverance, so that China can use globally innovative vaccines and the world can use high-quality Chinese vaccines!"!

▋ About Yither Bio

Yither Bio, established in 2020, is a wholly-owned subsidiary of Zhonghui Bio. Since its inception, it has adhered to the principle of not simply replicating the projects of its parent company. Instead, it has been committed to building an innovative R&D team with an international perspective and world-class capabilities, dedicated to the research, development, and industrialization of innovative vaccines for human use.
As of now, the company has established multiple technical platforms, including recombinant genetic engineering vaccine research platform, mRNA vaccine research platform, polysaccharide conjugate vaccine research platform, and innovative adjuvant research platform. It has also rapidly advanced the research, development, and production of multiple R&D pipelines, such as multivalent pneumococcal conjugate vaccine, recombinant shingles vaccine, recombinant respiratory syncytial virus vaccine, and mRNA poxvirus vaccine.